22nd May 2025
New UK Study Explore the Effectiveness of CELOX™ PPH vs Balloon Tamponade
Imperial College London Compares CELOX™ PPH vs Balloon Tamponade for Postpartum Haemorrhage (PPH)
Presented at BMFMS2025 | Belfast
We’re excited to announce that a new study from Imperial College London was presented at the British Maternal & Fetal Medicine Society (BMFMS) Congress this May! This comparative analysis explores the effectiveness of CELOX™ PPH haemostatic agent versus balloon tamponade in managing PPH in a tertiary maternity setting.
Why Does This Matter?
PPH remains a leading cause of maternal mortality and morbidity in the UK. The latest MBRRACE-UK 2024 report shows obstetric bleeding accounts for 7% of maternal deaths-highlighting the urgent need for effective solutions.
Study Snapshot
Setting: Tertiary maternity unit (Jan 2024 onwards)
Groups: CELOX™ PPH (n=12) vs Balloon Tamponade (n=17)
Objectives:
▪️ Effectiveness in controlling PPH
▪️ Blood loss, haemoglobin drop, transfusion needs, and time to haemostasis
▪️ Efficacy by PPH cause (atony, trauma, combined)
▪️ Safety, complications, and clinician feedback
Key Takeaways
▪️ Comparable Safety: No worse outcomes with CELOX™ PPH
▪️ Signals Reduced Blood Loss & Fewer Transfusions: Patients treated with CELOX™ PPH required fewer transfusions and had lower estimated blood loss (not statistically significant, but promising!)
▪️ Especially Effective in Trauma Cases: CELOX™ PPH proved especially effective in cases involving vaginal wall trauma
▪️ Cost-Effective: CELOX™ PPH offers a compelling cost benefit
▪️ More Research Underway: Ongoing studies will help refine patient selection and real-world use
This study further strengthens the evidence that CELOX™ PPH is a safe, effective, and cost-efficient solution for managing postpartum haemorrhage.
Explore More Clinical Evidence:
Visit our clinical evidence page for 12+ years of peer-reviewed studies and the latest insights on CELOX™ PPH.